title: [Inflammatory bowel diseases].
abstract: COX-2 specific anti-inflammatory agents appear as able to induce a flare of inflammatory bowel disease as classical anti-inflammatory agents. The use of steroids, immunomodulators or infliximab prior to surgery does not appear to increase post-operative complication rates. Cases of hepatitis B reactivation have been described after infliximab therapy, suggesting that hepatitis B serological status should be verified prior to infliximab therapy. Adalimubab, a fully humanized antibody directed against TNF-alpha, is efficacious in patients that have lost response or did not tolerate infliximab. Approval of this agent is still awaited. Leucoapheresis is a promising tool in ulcerative colitis.
authors.affiliation: Service de gastro-entérologie et d'hépatologie CHUV, 1011 Lausanne.
authors.forename: C
authors.initials: C
authors.lastname: Felley
authors.forename: J
authors.initials: J
authors.lastname: Guyot
authors.forename: J
authors.initials: J
authors.lastname: Hess
authors.forename: C
authors.initials: C
authors.lastname: Mottet
authors.forename: J
authors.initials: J
authors.lastname: Delarive
authors.forename: P
authors.initials: P
authors.lastname: Michetti
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha